CFI-402257 is primarily used in the field of cancer research and treatment. It functions as a potent and selective inhibitor of TTK protein kinase, which plays a critical role in cell division and chromosome stability. By targeting TTK, CFI-402257 disrupts the mitotic process in cancer cells, leading to their death. This makes it a promising candidate for the development of therapies targeting various cancers, particularly those with chromosomal instability. Researchers are exploring its potential in preclinical and clinical studies to evaluate its efficacy and safety in treating solid tumors and other malignancies. Additionally, it is being investigated in combination with other anticancer agents to enhance therapeutic outcomes.